
USD
$0.00
(0.00%
)At Close (As of Dec 11, 2025)
$598.66M
Market Cap
20.44
P/E Ratio
0.18
EPS
$5.13
52 Week High
$0.52
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $344M |
| Total Revenue | $351M |
| Cost Of Revenue | $7.6M |
| Costof Goods And Services Sold | $7.6M |
| Operating Income | $93M |
| Selling General And Administrative | $144M |
| Research And Development | $111M |
| Operating Expenses | $251M |
| Investment Income Net | - |
| Net Interest Income | -$29M |
| Interest Income | $4.5M |
| Interest Expense | $33M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $2M |
| Income Before Tax | $65M |
| Income Tax Expense | $64M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $880K |
| Comprehensive Income Net Of Tax | - |
| Ebit | $96M |
| Ebitda | $98M |
| Net Income | $880K |
| Field | Value (USD) |
|---|---|
| Gross Profit | $344M |
| Total Revenue | $351M |
| Cost Of Revenue | $7.6M |
| Costof Goods And Services Sold | $7.6M |
| Operating Income | $93M |
| Selling General And Administrative | $144M |
| Research And Development | $111M |
| Operating Expenses | $251M |
| Investment Income Net | - |
| Net Interest Income | -$29M |
| Interest Income | $4.5M |
| Interest Expense | $33M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $2M |
| Income Before Tax | $65M |
| Income Tax Expense | $64M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $880K |
| Comprehensive Income Net Of Tax | - |
| Ebit | $96M |
| Ebitda | $98M |
| Net Income | $880K |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
Ironwood Pharmaceuticals, Inc. is a prominent biotechnology firm headquartered in Boston, Massachusetts, specializing in the development and commercialization of innovative gastroenterological therapies. The company has a strong market presence driven by its flagship product, Linzess (linaclotide), and a robust pipeline aimed at addressing significant unmet medical needs in gastrointestinal disorders. Ironwood's strategic emphasis on research, development, and partnerships enhances its therapeutic offerings and positions it for sustainable growth, promising substantial long-term value for institutional investors while ultimately improving patient outcomes.